CR20230437A - Nuevos derivados de tiazolopirimidinona - Google Patents
Nuevos derivados de tiazolopirimidinonaInfo
- Publication number
- CR20230437A CR20230437A CR20230437A CR20230437A CR20230437A CR 20230437 A CR20230437 A CR 20230437A CR 20230437 A CR20230437 A CR 20230437A CR 20230437 A CR20230437 A CR 20230437A CR 20230437 A CR20230437 A CR 20230437A
- Authority
- CR
- Costa Rica
- Prior art keywords
- new
- thiazolopyrimidinone
- derivatives
- sup
- sub
- Prior art date
Links
- AKDQOJPOLRMVMF-UHFFFAOYSA-N [1,3]thiazolo[5,4-d]pyrimidine 3-oxide Chemical class N1=CN=C2S(=O)C=NC2=C1 AKDQOJPOLRMVMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a un compuesto de fórmula (I), en el que R<sup>1</sup>-R<sup>4</sup> y A<sub>1</sub>-A<sub>3</sub> son como se definen en la descripción y en las reivindicaciones. El compuesto de fórmula (I) se puede usar como un medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21163259 | 2021-03-17 | ||
PCT/EP2022/056586 WO2022194801A1 (en) | 2021-03-17 | 2022-03-15 | New thiazolopyrimidinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230437A true CR20230437A (es) | 2023-10-16 |
Family
ID=74947249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230437A CR20230437A (es) | 2021-03-17 | 2022-03-15 | Nuevos derivados de tiazolopirimidinona |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240018163A1 (es) |
EP (1) | EP4308576A1 (es) |
JP (1) | JP2024514421A (es) |
KR (1) | KR20230157367A (es) |
CN (1) | CN116981674A (es) |
AU (1) | AU2022240935A1 (es) |
BR (1) | BR112023018466A2 (es) |
CA (1) | CA3212341A1 (es) |
CL (1) | CL2023002705A1 (es) |
CO (1) | CO2023012574A2 (es) |
CR (1) | CR20230437A (es) |
IL (1) | IL305203A (es) |
MX (1) | MX2023010719A (es) |
TW (1) | TW202302604A (es) |
WO (1) | WO2022194801A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023520925A (ja) * | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調節するための化合物及び方法 |
EP4416156A1 (en) * | 2021-10-13 | 2024-08-21 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20142364A1 (es) | 2012-02-10 | 2015-01-10 | Hoffmann La Roche | Compuestos para tratar atrofia muscular espinal |
ES2761423T3 (es) | 2014-05-15 | 2020-05-19 | Hoffmann La Roche | Compuestos para tratar la atrofia muscular espinal |
EP3634953B1 (en) * | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
CA3067591A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
JP7075484B2 (ja) | 2017-09-22 | 2022-05-25 | エフ.ホフマン-ラ ロシュ アーゲー | 7-(4,7-ジアザスピロ[2.5]オクタン-7-イル)-2-(2,8-ジメチルイミダゾ[1,2-b]ピリダジン-6-イル)ピリド[1,2-a]ピリミジン-4-オン誘導体の製造方法 |
US11685746B2 (en) * | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
BR112020026534A2 (pt) * | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
JP2023520925A (ja) * | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調節するための化合物及び方法 |
-
2022
- 2022-03-15 CN CN202280021604.7A patent/CN116981674A/zh active Pending
- 2022-03-15 CR CR20230437A patent/CR20230437A/es unknown
- 2022-03-15 KR KR1020237032218A patent/KR20230157367A/ko unknown
- 2022-03-15 MX MX2023010719A patent/MX2023010719A/es unknown
- 2022-03-15 WO PCT/EP2022/056586 patent/WO2022194801A1/en active Application Filing
- 2022-03-15 AU AU2022240935A patent/AU2022240935A1/en active Pending
- 2022-03-15 CA CA3212341A patent/CA3212341A1/en active Pending
- 2022-03-15 JP JP2023556976A patent/JP2024514421A/ja active Pending
- 2022-03-15 BR BR112023018466A patent/BR112023018466A2/pt unknown
- 2022-03-15 IL IL305203A patent/IL305203A/en unknown
- 2022-03-15 EP EP22714821.0A patent/EP4308576A1/en active Pending
- 2022-03-16 TW TW111109552A patent/TW202302604A/zh unknown
-
2023
- 2023-09-11 CL CL2023002705A patent/CL2023002705A1/es unknown
- 2023-09-15 US US18/468,378 patent/US20240018163A1/en active Pending
- 2023-09-22 CO CONC2023/0012574A patent/CO2023012574A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202302604A (zh) | 2023-01-16 |
US20240018163A1 (en) | 2024-01-18 |
CO2023012574A2 (es) | 2023-09-29 |
CA3212341A1 (en) | 2022-09-22 |
JP2024514421A (ja) | 2024-04-02 |
BR112023018466A2 (pt) | 2023-10-10 |
CN116981674A (zh) | 2023-10-31 |
MX2023010719A (es) | 2023-09-20 |
WO2022194801A1 (en) | 2022-09-22 |
EP4308576A1 (en) | 2024-01-24 |
KR20230157367A (ko) | 2023-11-16 |
IL305203A (en) | 2023-10-01 |
CL2023002705A1 (es) | 2024-03-15 |
AU2022240935A1 (en) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023010719A (es) | Nuevos derivados de tiazolopirimidinona. | |
MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
MX2023012054A (es) | Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion. | |
SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
MY138941A (en) | Aryl-pyridine derivatives | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
MX2009010567A (es) | Derivados de imidazolidinona. | |
MX2010003224A (es) | Derivados de biaril sulfonamida. | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
PL401636A1 (pl) | Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna | |
MX2007009777A (es) | Derivados de triazol. | |
TW200616940A (en) | Novel hexafluoroisopropanol substituted ether derivatives | |
CR20200643A (es) | Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 | |
MX2022006711A (es) | Nuevos inhibidores de braf como rompedores de la paradoja. | |
MX2010002341A (es) | Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. | |
MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
MY145464A (en) | Pyrazolone derivatives as 11-beta hsd1 inhibitors | |
MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
PH12018502012A1 (en) | Griseofulvin compound | |
MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
MX2010005164A (es) | Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide. | |
GB0314967D0 (en) | Piperazine derivatives | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same |